Inhibikase Therapeutics Terminates Material Agreement
Ticker: IKT · Form: 8-K · Filed: Dec 5, 2024 · CIK: 1750149
| Field | Detail |
|---|---|
| Company | Inhibikase Therapeutics, INC. (IKT) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $5,659,255, $849,187.85, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement-termination, corporate-action
TL;DR
Inhibikase terminated a big deal, expect news soon.
AI Summary
Inhibikase Therapeutics, Inc. announced on December 2, 2024, the termination of a material definitive agreement. The company, incorporated in Delaware, is based in Atlanta, Georgia, and operates in the biological products sector.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, partnerships, and financial outlook.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement often signals significant business changes or challenges that could affect the company's future performance.
Key Numbers
- 001-39676 — SEC File Number (Identifies the company's filing with the SEC.)
- 26-3407249 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- December 2, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Atlanta, Georgia (location) — Principal executive offices location
- 3350 Riverwood Parkway SE, Suite 1900 (address) — Principal executive offices address
FAQ
What specific material definitive agreement was terminated?
The filing does not specify the exact name or details of the material definitive agreement that was terminated.
What is the effective date of the termination?
The earliest event reported is December 2, 2024, which is the date of the report and likely the effective date or announcement date of the termination.
What are the reasons for the termination of the agreement?
The filing does not provide the reasons for the termination of the material definitive agreement.
Will this termination have a significant impact on Inhibikase Therapeutics' financial condition or operations?
The filing states it is a 'material definitive agreement,' implying it could have a significant impact, but the extent is not detailed.
Are there any other agreements or contracts that are affected by this termination?
The filing does not mention any other agreements or contracts being affected by this specific termination.
Filing Stats: 609 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-12-05 16:50:29
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
- $5,659,255 — in an aggregate offering price of up to $5,659,255, through or to the Agent. Under the ter
- $849,187.85 — t for an aggregate gross sales price of $849,187.85. On May 20, 2024, the Company filed wit
- $50,000 — greement from and after May 20, 2024 to $50,000, not including the shares of the Compan
Filing Documents
- d914736d8k.htm (8-K) — 24KB
- 0001193125-24-271609.txt ( ) — 146KB
- ikt-20241202.xsd (EX-101.SCH) — 3KB
- ikt-20241202_lab.xml (EX-101.LAB) — 18KB
- ikt-20241202_pre.xml (EX-101.PRE) — 11KB
- d914736d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 5, 2024 INHIBIKASE THERAPEUTICS, INC. By: /s/ Milton H. Werner Name: Milton H. Werner, Ph.D. Title: President and Chief Executive Officer